查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
北美抗體藥物偶聯物市場預測至 2030 年 - 區域分析 - 按技術、應用和配銷通路
市場調查報告書
商品編碼
1481965

北美抗體藥物偶聯物市場預測至 2030 年 - 區域分析 - 按技術、應用和配銷通路

North America Antibody Drug Conjugates Market Forecast to 2030 - Regional Analysis - By Technology, Application, and Distribution Channel
出版日期: | 出版商: The Insight Partners | 英文 100 Pages | 訂單完成後即時交付

價格

2022年北美抗體藥物偶聯物市值為36.5981億美元，預計2030年將達到136.8158億美元；預計2022年至2030年複合年成長率為17.9%。

FDA 對 ADC 的批准不斷增加，推動了北美抗體藥物偶聯物市場的發展

根據2021 年9 月發表在美國國家醫學圖書館的一篇文章《An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy for Cancer Therapy》，2017 年ADC 批准數量為8 個，2021 年9 月增加至11個。這些公司主要針對血癌和其他癌症類型，如肺癌、膀胱癌和婦科腫瘤。此外，2021年6月，美國投資銀行Evercore和Evercore ISI預計，到2030年，兩家公司每年的ADC銷售額將超過200億美元。 ADC 的批准和商業化不斷增加，導致市場顯著成長。以下是 FDA 批准的 ADC 清單。

  • 表 1. FDA 核准的 ADC 列表

序號 公司商品名稱 ADC 藥物癌症類型核准年份

1 輝瑞/惠氏 Mylotarg Gemtuzumab ozogamicin 復發性急性髓性白血病 (AML) 2000； 2017年

2 Seagen Genetics，Millennium/Takeda Adcetris Brentuximab vedotin 復發 HL 與復發 sALCL 2011

3 基因泰克、羅氏 Kadcyla 曲妥珠單抗 emtansine HER2 陽性轉移性乳癌 (mBC) 2013

4 輝瑞/惠氏 Besponsa Inotuzumab ozogamicin 復發或難治性 CD22 陽性 B 細胞前驅急性淋巴母細胞白血病2017

5 阿斯特捷利康 Lumoxiti Moxetumomab pasudotox 成人復發或難治性毛細胞白血病 (HCL) 2018

6 基因泰克、羅氏 Polivy Polatuzumab vedotin-piiq 復發或難治性瀰漫性大 B 細胞淋巴瘤 (DLBCL) 2019

7 Astellas/Seagen Genetics Padcev Enfortumab vedotin 接受 PD-1 或​​ PD-L1 抑制劑以及含 Pt 治療的成人轉移性尿路上皮癌 2019

8 阿斯利康/第一三共 Enhertu 曲妥珠單抗 deruxtecan 成人轉移性 HER2 陽性乳癌，既往接受過兩種或多種抗 HER2 治療方案 2019

9 免疫醫學 Trodelvy Sacituzumab govitecan 成人轉移性三陰性乳癌 (mTNBC)，以及接受過至少兩種先前治療的復發或難治性轉移性疾病患者 2020

10 葛蘭素史克 (GSK) Blenrep Belantamab mafodotin-blmf 2020 年成人復發或難治性多發性骨髓瘤，於 2022 年 11 月 22 日在美國撤回。

11 ADC 療法 Zynlonta Loncastuximab tesirine-lpyl 大 B 細胞淋巴瘤 2021

12 Seagen Inc Tivdak Tisotumab vedotin-tftv 復發性或轉移性子宮頸癌 2021

13 ImmunoGen Elahere Mirvetuximab soravtansine 鉑金抗藥性卵巢癌 2022

北美抗體藥物偶聯物市場概況

基於美國、加拿大和墨西哥對北美抗體藥物偶聯物（ADC）市場進行了分析。該地區的市場成長歸因於 ADC 研發的增加、產品批准的增加、對 ADC 認知的提高以及營運商之間合併、合作和夥伴關係數量的增加。此外，癌症發生率的顯著增加是對 ADC 需求增加的其他主要因素之一。

此外，公司之間不斷加強合作以在不同地區擴展其技術，從而促進市場成長。 2023 年 8 月，ImmunoGen, Inc. 和武田製藥有限公司在日本合作開發和商業化 ELAHERE（免疫原 ADC 療法）。根據合作協議，ImmunoGen, Inc. 在獲得 FDA 加速批准 ELAHERE 用於治療鉑類抗藥性卵巢癌後將獲得預付款和額外付款。如果武田透過ELAHERE 在日本的淨銷售額實現了某些監管和商業里程碑以及兩位數的特許權使用費，它將向ImmunoGen, Inc.支付額外款項。並將供應該產品進行開發和銷售。作為回報，武田將負責所有監管備案，並擁有在日本開發和商業化 ELAHERE 的獨家許可。

北美抗體藥物偶聯物市場收入及 2030 年預測（百萬美元）

北美抗體藥物偶聯物市場細分

北美抗體藥物偶聯物市場根據技術、應用、配銷通路和國家進行細分。

基於技術，北美抗體藥物偶聯物市場抗體藥物偶聯物市場分為可裂解接頭和不可裂解接頭。 2022 年，可裂解連接子部分佔據了更大的佔有率。

根據應用，北美抗體藥物偶聯物市場抗體藥物偶聯物市場分為血癌、乳癌、卵巢癌、尿路上皮癌等。 2022 年，乳癌細分市場所佔比重最大。

根據配銷通路，北美抗體藥物偶聯物市場抗體藥物偶聯物市場分為醫院藥房、零售藥房和線上藥房。 2022年，醫院藥局部門佔最大佔有率。

根據國家/地區，北美抗體藥物偶聯物市場分為美國、加拿大和墨西哥。 2022年，美國主導北美抗體藥物偶聯物市場。

ADC Therapeutics SA、輝瑞公司、羅氏公司、ImmunoGen 公司、葛蘭素史克公司、吉利德科學公司、阿斯利康公司、安斯泰來製藥公司、榮昌生物有限公司和武田製藥有限公司是在北方營運的一些領先公司美國抗體藥物偶聯物市場。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 市場吸引力

第 3 章：研究方法

  • 覆蓋範圍
  • 二次研究
  • 初步研究

第 4 章：北美抗體藥物偶聯物市場 - 主要產業動態

  • 主要市場促進因素：
    • 加強策略夥伴關係開發抗體藥物偶聯物
    • 癌症發生率上升
    • FDA 增加對 ADC 的核准
  • 市場限制
    • ADC 開發和商業化成本高昂
  • 市場機會
    • 增加開發 ADC 的投資
  • 市場走向
    • 不斷升級的 ADC 產品線
  • 影響分析：

第 5 章：抗體藥物偶聯物市場 - 北美市場分析

  • 北美抗體藥物偶聯物市場收入，2017 - 2030

第 6 章：北美抗體藥物偶聯物市場 - 收入和 2030 年預測 - 按技術

  • 概述
  • 北美抗體藥物偶聯物市場收入佔有率，按技術分類 2022 年和 2030 年 (%)
  • 可切割接頭
  • 不可切割的接頭

第 7 章：北美抗體藥物偶聯物市場 - 收入和 2030 年預測 - 按應用

  • 概述
  • 2022 年和 2030 年北美抗體藥物偶聯物市場收入佔有率（按應用分類）
  • 血癌
  • 乳癌
  • 卵巢癌
  • 尿路上皮癌
  • 其他

第 8 章：北美抗體藥物偶聯物市場 - 收入和 2030 年預測 - 按配銷通路

  • 概述
  • 2022 年及 2030 年北美抗體藥物偶聯物市場收入佔有率（按配銷通路）（%）
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 9 章：北美抗體藥物偶聯物市場 - 國家分析

    • 北美洲
      • 美國
      • 加拿大
      • 墨西哥

第 10 章：抗體藥物偶聯物市場-產業格局

  • 概述
  • 有機成長策略
    • 概述
  • 無機成長策略
    • 概述
  • 公司製造能力及能力

第 11 章：公司簡介

  • ADC Therapeutics SA
  • Pfizer Inc
  • Hoffmann-La Roche Ltd
  • ImmunoGen, Inc.
  • GSK Plc
  • Gilead Sciences Inc
  • AstraZeneca Plc
  • Astellas Pharma Inc
  • RemeGen Co Ltd
  • Takeda Pharmaceutical Co Ltd

第 12 章：附錄

Product Code: BMIRE00029767

The North America antibody drug conjugates market was valued at US$ 3,659.81 million in 2022 and is expected to reach US$ 13,681.58 million by 2030; it is estimated to grow at a CAGR of 17.9% from 2022 to 2030.

Increasing FDA Approvals for ADCs Fuels the North America Antibody Drug Conjugates Market

According to an article, An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy, published in the National Library of Medicine in September 2021, there were eight approvals for ADC in 2017, and it increased to 11 in September 2021. The FDA has approved a few more ADCs, including Lumoxiti, till the end of November 2022. Worldwide, more than 50 biopharmaceutical companies are involved in developing ADCs. The companies have targeted mainly blood cancer and other cancer types, such as lung, bladder, and gynecological tumors. Additionally, in June 2021, Evercore, a US-based Investment Banking and Evercore ISI, estimated that by 2030, the companies will sell ADCs for over US$ 20 billion annually. The increasing approvals and commercialization of ADCs are leading to significant market growth. Below is a list of FDA-approved ADCs.

  • Table 1. List of FDA-Approved ADCs

Sr. No. Company Trade Name ADC Drug Cancer Type Approval Year

1 Pfizer/Wyeth Mylotarg Gemtuzumab ozogamicin Relapsed Acute Myelogenous Leukemia (AML) 2000; 2017

2 Seagen Genetics, Millennium/Takeda Adcetris Brentuximab vedotin Relapsed HL and Relapsed sALCL 2011

3 Genentech, Roche Kadcyla Trastuzumab emtansine HER2-positive Metastatic Breast Cancer (mBC) 2013

4 Pfizer/Wyeth Besponsa Inotuzumab ozogamicin Relapsed or Refractory CD22-positive B-cell Precursor Acute Lymphoblastic Leukemia 2017

5 Astrazeneca Lumoxiti Moxetumomab pasudotox Relapsed or refractory hairy cell leukaemia (HCL) in adults 2018

6 Genentech, Roche Polivy Polatuzumab vedotin-piiq Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) 2019

7 Astellas/Seagen Genetics Padcev Enfortumab vedotin Metastatic urothelial cancer in adult who have received a PD-1 or PD-L1 inhibitor, and a Pt-containing therapy 2019

8 AstraZeneca/Daiichi Sankyo Enhertu Trastuzumab deruxtecan Metastatic HER2-positive breast cancer in adults, received two or more prior anti-HER2 based regimens 2019

9 Immunomedics Trodelvy Sacituzumab govitecan Metastatic triple-negative breast cancer (mTNBC) in adults, and patients received minimum two prior therapies for patients with relapsed or refractory metastatic disease 2020

10 GlaxoSmithKline (GSK) Blenrep Belantamab mafodotin-blmf Relapsed or refractory multiple myeloma in adults 2020, withdrawn on 22 Nov. 2022 in the US.

11 ADC Therapeutics Zynlonta Loncastuximab tesirine-lpyl Large B-cell lymphoma 2021

12 Seagen Inc Tivdak Tisotumab vedotin-tftv Recurrent or metastatic cervical cancer 2021

13 ImmunoGen Elahere Mirvetuximab soravtansine Platinum-resistant ovarian cancer 2022

North America Antibody Drug Conjugates Market Overview

The antibody drug conjugates (ADCs) market in North America is analyzed based on the US, Canada, and Mexico. The market growth in the region is attributed to increasing research and development for ADCs, rising product approvals, growing awareness about ADCs, and rising number of mergers, collaborations, and partnerships among the operating players. In addition, significantly growing incidences of cancer are among the other leading factors escalating the demand for ADCs.

Furthermore, growing partnerships among the companies to expand their technologies in different regions enable market growth. In August 2023, ImmunoGen, Inc. and Takeda Pharmaceutical Company Limited collaborated to develop and commercialize ELAHERE, Immunogens ADC therapy, in Japan. Under the collaboration agreement, ImmunoGen, Inc. receives upfront and additional payments upon conversion of FDA accelerated approval of ELAHERE to treat platinum-resistant ovarian cancer. If Takeda achieves certain regulatory and commercial milestones and double-digit royalties through the net sales of ELAHERE in Japan, it will pay an additional payment to ImmunoGen, Inc. Nevertheless, Immunogen has retained its exclusive production rights and will supply the product for development and commercialization in Japan. In return, Takeda will be responsible for all regulatory filing and have an exclusive license to develop and commercialize ELAHERE in Japan.

North America Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Million)

North America Antibody Drug Conjugates Market Segmentation

The North America antibody drug conjugates market is segmented based on technology, application, distribution channel, and country.

Based on technology, the North America antibody drug conjugates market antibody drug conjugates market is bifurcated into cleavable linker and non-cleavable linker. The cleavable linker segment held a larger share in 2022.

Based on application, the North America antibody drug conjugates market antibody drug conjugates market is segmented into blood cancer, breast cancer, ovarian cancer, urothelial cancer, and others. The breast cancer segment held the largest share in 2022.

Based on distribution channel, the North America antibody drug conjugates market antibody drug conjugates market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest share in 2022.

Based on country, the North America antibody drug conjugates market is categorized into US, Canada, and Mexico. The US dominated the North America antibody drug conjugates market in 2022.

ADC Therapeutics SA, Pfizer Inc, Hoffmann-La Roche Ltd, ImmunoGen, Inc, GSK Plc, Gilead Sciences Inc, AstraZeneca Plc, Astellas Pharma Inc, RemeGen Co Ltd, and Takeda Pharmaceutical Co Ltd are some of the leading companies operating in the North America antibody drug conjugates market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Market Attractiveness

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Antibody Drug Conjugates Market - Key Industry Dynamics

  • 4.1 Key Market Drivers:
    • 4.1.1 Growing Strategic Partnerships to Develop Antibody Drug Conjugates
    • 4.1.2 Rising Incidences of Cancer Cases
    • 4.1.3 Increasing FDA Approvals for ADCs
  • 4.2 Market Restraints
    • 4.2.1 High Cost of ADCs Development and Commercialization
  • 4.3 Market Opportunities
    • 4.3.1 Increasing Investments to Develop ADCs
  • 4.4 Market Trends
    • 4.4.1 Escalating Pipeline of ADCs
  • 4.5 Impact Analysis:

5. Antibody Drug Conjugates Market - North America Market Analysis

  • 5.1 North America Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 - 2030

6. North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Technology

  • 6.1 Overview
  • 6.2 North America Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
  • 6.3 Cleavable Linker
    • 6.3.1 Overview
    • 6.3.2 Cleavable Linker: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Non-cleavable Linker
    • 6.4.1 Overview
    • 6.4.2 Non-cleavable Linker: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

7. North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Application

  • 7.1 Overview
  • 7.2 North America Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
  • 7.3 Blood Cancer
    • 7.3.1 Overview
    • 7.3.2 Blood Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Breast Cancer
    • 7.4.1 Overview
    • 7.4.2 Breast Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Ovarian Cancer
    • 7.5.1 Overview
    • 7.5.2 Ovarian Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.6 Urothelial Cancer
    • 7.6.1 Overview
    • 7.6.2 Urothelial Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.7 Others
    • 7.7.1 Overview
    • 7.7.2 Others: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Distribution Channel

  • 8.1 Overview
  • 8.2 North America Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
  • 8.3 Hospital Pharmacies
    • 8.3.1 Overview
    • 8.3.2 Hospital Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Retail Pharmacies
    • 8.4.1 Overview
    • 8.4.2 Retail Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Online Pharmacies
    • 8.5.1 Overview
    • 8.5.2 Online Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Antibody Drug Conjugates Market - Country Analysis

  • 9.1 North America Antibody Drug Conjugates Market, Revenue and Forecast To 2030
    • 9.1.1 Overview
    • 9.1.2 North America Antibody Drug Conjugates Market Breakdown, by Country Revenue (2022) (US$ Million)
    • 9.1.3 North America: Antibody Drug Conjugates Market, by Countries,2022 and 2030 (%)
      • 9.1.3.1 US
        • 9.1.3.1.1 Overview
        • 9.1.3.1.2 US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.3.1.3 US: Antibody Drug Conjugates Market, by Technology
        • 9.1.3.1.4 US: Antibody Drug Conjugates Market, by Application
        • 9.1.3.1.5 US: Antibody Drug Conjugates Market, by Distribution Channel
      • 9.1.3.2 Canada
        • 9.1.3.2.1 Overview
        • 9.1.3.2.2 Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.3.2.3 Canada: Antibody Drug Conjugates Market, by Technology
        • 9.1.3.2.4 Canada: Antibody Drug Conjugates Market, by Application
        • 9.1.3.2.5 Canada: Antibody Drug Conjugates Market, by Distribution Channel
      • 9.1.3.3 Mexico
        • 9.1.3.3.1 Overview
        • 9.1.3.3.2 Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.3.3.3 Mexico: Antibody Drug Conjugates Market, by Technology
        • 9.1.3.3.4 Mexico: Antibody Drug Conjugates Market, by Application
        • 9.1.3.3.5 Mexico: Antibody Drug Conjugates Market, by Distribution Channel

10. Antibody Drug Conjugates Market-Industry Landscape

  • 10.1 Overview
  • 10.2 Organic Growth Strategies
    • 10.2.1 Overview
  • 10.3 Inorganic Growth Strategies
    • 10.3.1 Overview
  • 10.4 Companies' Manufacturing Capacities and Capabilities

11. Company Profiles

  • 11.1 ADC Therapeutics SA
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 Pfizer Inc
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Hoffmann-La Roche Ltd
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 ImmunoGen, Inc.
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 GSK Plc
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Gilead Sciences Inc
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 AstraZeneca Plc
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 Astellas Pharma Inc
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 RemeGen Co Ltd
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments
  • 11.10 Takeda Pharmaceutical Co Ltd
    • 11.10.1 Key Facts
    • 11.10.2 Business Description
    • 11.10.3 Products and Services
    • 11.10.4 Financial Overview
    • 11.10.5 SWOT Analysis
    • 11.10.6 Key Developments

12. Appendix

  • 12.1 About Us
  • 12.2 Glossary of Terms

List Of Tables

  • Table 1. North America Antibody Drug Conjugates Market Segmentation
  • Table 2. New Cancer Cases Worldwide, in 2020
  • Table 3. List of FDA-Approved ADCs
  • Table 4. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 5. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 6. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 7. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 8. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 9. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 10. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
  • Table 11. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
  • Table 12. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
  • Table 13. Recent Organic Growth Strategies in Antibody Drug Conjugates Market
  • Table 14. Recent Inorganic Growth Strategies in the Antibody Drug Conjugates Market
  • Table 15. Glossary of Terms, Antibody Drug Conjugates Market

List Of Figures

  • Figure 1. North America Antibody Drug Conjugates Market Segmentation, By Country
  • Figure 2. Key Insights
  • Figure 3. North America Antibody Drug Conjugates Market - Key Industry Dynamics
  • Figure 4. Impact Analysis of Drivers and Restraints
  • Figure 5. North America Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 - 2030
  • Figure 6. North America Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
  • Figure 7. Cleavable Linker: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Non-Cleavable Linker: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. North America Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
  • Figure 10. Blood Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Breast Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Ovarian Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Urothelial Cancer: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. Others: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. North America Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
  • Figure 16. Hospital Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. Retail Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Online Pharmacies: North America Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 19. North America Antibody Drug Conjugates, by Key Country - Revenue (2022) (US$ Million)
  • Figure 20. North America: Antibody Drug Conjugates Market, By Key Countries, 2022 and 2030 (%)
  • Figure 21. US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 22. Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 23. Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)